Poor focus and anxiety aren't enough to tell whether Semax/Selank is right for you. If you're asking “should I take Semax Selank?”, the assessment comes first. Maya, 38, is a fictional composite with persistent attention complaints, an anxiety diagnosis, and an existing prescription for anxiety.
Her question has two parts: what's behind the symptoms, and what evidence would justify adding anything to her care? Semax and Selank are peptides, short chains of protein building blocks. Research on each ingredient doesn't automatically answer questions about the pair.
Should I take Semax Selank? First, what needs assessment?
The provider starts with what Maya means by poor focus. Does she lose track of conversations, miss deadlines, or struggle mainly after nights of broken sleep? When did that begin? What changed around the same time?
Those details help distinguish a persistent pattern from a recent change. The National Institute of Mental Health's adult ADHD guide describes reviewing mood and medical conditions to consider other explanations. ADHD means attention-deficit/hyperactivity disorder, a condition involving persistent attention difficulties, restlessness, or impulsive behavior that interferes with daily life.
If the cause remains unclear, the next branch is assessment. Adding a peptide wouldn't explain why the symptoms started. Maya's sleep, anxiety, medication history, and daily difficulties all belong in that conversation.
What does her existing diagnosis explain?
Maya has an anxiety diagnosis, but she hasn't been assessed for ADHD. Her provider asks whether concentration problems began in childhood, appear across settings, and persist when anxiety is less intrusive. Anxiety and an attention disorder can coexist; one label doesn't automatically explain everything.
If an established condition needs further care, that review comes next. A peptide request doesn't replace it. The separate guides to Semax for ADHD and Selank for anxiety cover the condition-specific evidence.
The question now is whether evidence about either ingredient actually matches Maya's concern about the two-peptide preparation.
What changes because she already takes a prescription?
The provider needs the medicine's name, amount, recent changes, and who manages it. “Something for anxiety” leaves too much unanswered. Nonprescription sleep aids, supplements, alcohol, and other compounds used for focus also belong in the review.
There is some human combination research, but it concerns a different pairing. A 2015 study in the S.S. Korsakov neurology and psychiatry journal examined Selank alongside phenazepam, an anti-anxiety medicine. It did not test Semax/Selank alongside Maya's prescription.
If compatibility is uncertain, that question remains open. One study involving a different medicine can't clear every combination. Any changes to Maya's existing psychiatric care remain with the clinician managing it. Interest in peptides supplies no reason to replace or taper that care.
Which human evidence fits her question?
The provider separates the studies by who received what. In Zozulia and colleagues' 2008 study, published in the same Russian journal, 62 people had generalized anxiety disorder or neurasthenia. Generalized anxiety disorder involves persistent, hard-to-control worry; neurasthenia is an older diagnosis involving exhaustion and related symptoms.
Thirty received Selank and 32 received medazepam, another anti-anxiety medicine. The authors reported similar anxiety effects. That small comparison used another active medicine rather than placebo, an inactive comparison preparation. It tested Selank alone, not Semax/Selank.
The Semax paper involving fluvoxamine, a medicine used for depression, answers a different question. Glazova and colleagues' study in Neuropeptides, 2021 examined rats exposed to fluvoxamine early in life, followed by Semax. It measured animal behavior and brain chemicals. It wasn't a human anxiety or attention trial, or a study of adults taking both medicines together.
For Maya, neither paper supplies a dependable chance of benefit from the pair.
Was the pair tested for her problem?
A 2020 study in Doklady Biological Sciences included 52 healthy people. They received Semax, Selank, or placebo in separate groups. Researchers measured brain activity patterns with scans before treatment and at five and 20 minutes afterward.
Those short-term scan findings don't establish anxiety relief or better everyday concentration. The experiment also didn't give both peptides together. Available human studies do not establish the pair's benefits for Maya's combination of symptoms.
If her expectation is predictable calmer focus, the evidence doesn't support that prediction. Her provider would need to discuss that gap before considering a prescription.
Does the new policy answer her treatment question?
As of November 5, 2026, the day this article was written, HHS's October 30 Federal Register notice announces a draft peptide compounding policy. HHS is the Department of Health and Human Services. Its policy text describes when it does not intend to take enforcement action, with all ten conditions required. Appendix A lists Semax; Selank isn't listed. The HHS policy explainer covers the details.
The notice says the draft creates no legal rights and leaves final ingredient-list decisions to separate federal rules. It adds no clinical trial result for Maya's symptoms.
Semax/Selank prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not review compounded drugs for safety, effectiveness, or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
What would the decision and follow-up need to settle?
The remaining conversation concerns Maya's goal, the uncertainties she understands, and how any proposed plan would be reviewed. Fewer missed tasks and less worry are different goals. A brain scan can't choose between them.
The provider also considers prior drug reactions, other health conditions, and pregnancy or breastfeeding. If anything is prescribed, the prescriber sets the actual dose and follow-up plan. A licensed U.S. compounding pharmacy prepares and dispenses the medication.
The questions to bring before Semax/Selank provide a checklist for that conversation. For Maya, the next step remains a discussion with her clinician about what fits her history and goals.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
